Stay updated on Imatinib in Recurrent Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Imatinib in Recurrent Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Imatinib in Recurrent Psoriasis Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed.
    Difference
    0.1%
    Check dated 2026-03-28T01:42:24.000Z thumbnail image
  2. Check
    20 days ago
    No Change Detected
  3. Check
    27 days ago
    Change Detected
    Summary
    A new revision entry v3.4.3 was added. The previous entry v3.4.2 was removed.
    Difference
    0.1%
    Check dated 2026-03-06T19:02:57.000Z thumbnail image
  4. Check
    48 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.2 instead of Revision: v3.4.1, indicating a minor version update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T12:25:52.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-05T14:17:47.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4 in the page footer.
    Difference
    0.1%
    Check dated 2026-01-15T03:01:08.000Z thumbnail image
  7. Check
    99 days ago
    Change Detected
    Summary
    Added a new Locations section with Maryland as a location, expanding where the study is conducted. The page footer now shows Revision: v3.3.3, and the Maryland Locations entry was removed.
    Difference
    0.2%
    Check dated 2025-12-24T14:58:25.000Z thumbnail image

Stay in the know with updates to Imatinib in Recurrent Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Imatinib in Recurrent Psoriasis Clinical Trial page.